GC Cell has signed a memorandum of understanding (MOU) with PT Bifarma Adiluhung to introduce Immuncell-LC, an autologous T-cell therapy for hepatocellular carcinoma (HCC), to the Indonesian healthcare market. The strategic deal between the two companies facilitates the entry of the therapy into the country, thereby expanding its reach. The gold standard of business intelligence.
Immuncell-LC is the only approved treatment for liver cancer in Korea. The deal encompasses not only the introduction of Immuncell-LC in Indonesia but also talks on technology transfer and the joint development of further natural killer (NK) cell therapy pipelines. GC Cell recently launched its Blueprint 2.
0 strategy, which underscores a strategic shift towards developing future growth drivers, including the global commercialisation of its cell therapy products. Immuncell-LC is at the forefront of this global expansion, especially in Asia-Pacific. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form GC Cell CEO James Park stated: “This partnership is a testament to the global recognition of our cell therapy expertise, first established in Korea. “By combining GC .